Evaxion finalizes agreement with eib to convert debt into equity

Copenhagen, denmark, july 11, 2025 - evaxion a/s (nasdaq: evax) (“evaxion”), a clinical-stage techbio company specializing in developing ai-immunology™ powered vaccines, has finalized its agreement with the european investment bank (eib) to convert debt into equity.
EVAX Ratings Summary
EVAX Quant Ranking